Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Shionogi: Anti-Flu Agent Rapiacta
February 8, 2010
- Re-Pricing of Tasigna, Sprycel “Appropriate” Mr Isobe
February 8, 2010
- JCR Aims at 20% Share for EPO Biosimilar: President Ashida
February 8, 2010
- Rozerem Recommended for Approval
February 8, 2010
- DSP to Transfer Growth Hormone Business to JCR
February 8, 2010
- PMDA Needs Internal Renovation: Prof. Kami
February 8, 2010
- Pregabalin to Drive Pfizer's Primary Case Business: Mr Harada
February 8, 2010
- Panel on Unapproved Drugs to Hold 1st Meeting
February 8, 2010
- Kyowa Kirin Aims at Pharm. Sales of \225.0 Bil. in FY2012
February 8, 2010
- Medical Fees Up for the 1st Time in 10 Years, But Drug Prices Down 6.5%
February 8, 2010
- Zeria to Overcome NHI Price Cuts through Synergism with Tillotts: President Ibe
February 8, 2010
- Present Scientific Grounds for Combination Drugs
February 8, 2010
- FDA Extends PDUFA Date for Sepracor's STEDESA NDA
February 8, 2010
- Price Cuts for Long-Listed Drugs to Harshly Hit Mochida: President Mochida
February 8, 2010
- Gemzar Recommended for Approval for Breast Cancer
February 8, 2010
- Fluzone High-Dose Approved for Elderly Patients in the US: sanofi-aventis
February 8, 2010
- 1 in 5 Does Not Finish Full-Course Tamiflu Treatment
February 8, 2010
- Takara Bio Accelerates Commercialization of Gene, Cell Therapy
February 8, 2010
- Januvia, Glactiv Ranked No. 1, 2 on Both GP, HP Markets
February 8, 2010
- JSCTR to Certify Clinical Trial Monitors
February 8, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…